Nancy Wysenski sold $1.3M of ALKS
director at Alkermes plc.. 41,250 shares at an average of $31.24, traded May 9, 2023, filed May 10, 2023.
Score components
- +15RoleDirector
- +25Trade size$1.3M at market
- +20Share of holdings soldSold 72% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-23-015117, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 9, 2023 | MOption exercise Ordinary Shares10b5-1 | +35,000 | $31.13 | $1.1M | 50,829 | May 10, 2023 |
| May 9, 2023 | MOption exercise Ordinary Shares10b5-1 | +6,250 | $31.13 | $195k | 57,079 | May 10, 2023 |
| May 9, 2023 | SOpen-market sale Ordinary Shares10b5-1 | -41,250 | $31.24 | $1.3M | 15,829 | May 10, 2023 |
| May 9, 2023 | MOption exercise Non Qualified Stock Option (Right to Buy)derivative10b5-1 | -35,000 | $0.00 | $0 | 0 | May 10, 2023 |
| May 9, 2023 | MOption exercise Non Qualified Stock Option (Right to Buy)derivative10b5-1 | -6,250 | $0.00 | $0 | 0 | May 10, 2023 |
Related signals
Other insiders at Alkermes plc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 4Weak | Alkermes plc. | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | $83k 2,034 shares | -1% | |
| 13Weak | Alkermes plc. | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | $98k 2,034 shares | -1% | |
| 9Weak | Alkermes plc. | Craig C. Hopkinson EVP R&D, Chief Medical Officer | $423k 9,000 shares | -12% | |
| 25Weak | Alkermes plc. | Christian Todd Nichols SVP, Chief Commercial Officer | $373k 7,576 shares | -7% | |
| 20Weak | Alkermes plc. | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | $99k 2,034 shares | -1% | |
| 17Weak | Alkermes plc. | Craig C. Hopkinson EVP R&D, Chief Medical Officer | $437k 9,000 shares | -11% | |
| 60Notable | Alkermes plc. | nancy lynn snyderman MD director | $2.2M 44,472 shares | -74% | |
| 13Weak | Alkermes plc. | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | $110k 2,034 shares | -1% | |
| 10Weak | Alkermes plc. | Craig C. Hopkinson EVP R&D, Chief Medical Officer | $464k 9,000 shares | -11% | |
| 19Weak | Alkermes plc. | Christopher I Wright director | $90k 2,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.